Results 161 to 170 of about 22,470,337 (287)

Case Report: Diagnostic pitfall and biomarker-guided therapy in CD20-negative Epstein-Barr virus-positive diffuse large B-cell lymphoma. [PDF]

Front Immunol
Wen J, Zhao C, Chen S, Chen X, Lv Q, Liu W, Wang J, Chen D.   +7 more
europepmc   +1 more source

Return to work for patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation

, 2017
Bente Arboe,1,2 Maja Halgren Olsen,2 Jette Soenderskov Goerloev,1 Anne Katrine Duun-Henriksen,2 Christoffer Johansen,2,3 Susanne Oksbjerg Dalton,2 Peter de Nully Brown1 1Department of Hematology, Copenhagen University Hospital, Rigshospitalet, 2Unit of ...
Olsen MH, Duun-Henriksen AK, Johansen C, Dalton SO, Goerloev JS, Brown PDN, Arboe B   +6 more
core  

Review Article: Immune Effector Cell‐Mediated Enterocolitis Following CAR‐T Cell Therapy—Clinical Features, Pathophysiology and Management

Alimentary Pharmacology &Therapeutics, EarlyView.
Immune effector cell‐mediated enterocolitis is an emerging complication of CAR‐T therapy. This review summarizes its epidemiology, pathophysiology, diagnosis, endoscopic and histopathologic features, and evidence‐based management, emphasizing early recognition, multidisciplinary intervention, and step‐up therapy.
John A. Damianos, Yi Lin, Zongming Eric Chen, Kenneth J. C. Lim, Navreet M. Chowla   +4 more
wiley   +1 more source

Primary Colonic Diffuse Large B-cell Lymphoma: A Diagnostic Challenge. [PDF]

Cureus
Montero S.
europepmc   +1 more source

Case Report: Sinonasal plasmablastic lymphoma in a human immunodeficiency virus-negative elderly woman diagnosed by immunohistochemistry. [PDF]

Front Med (Lausanne)
Nerune SM, Das SK, Ajur S, Garg I.
europepmc   +1 more source

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma: Phase 1b dose‐escalation study

British Journal of Haematology, EarlyView.
Summary Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R‐CHOP) in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (B‐NHL) who had ≥1 prior obinutuzumab/rituximab‐containing therapy (NCT03467373). The primary end‐point was to determine the optimal biological dose of
William Townsend, Nilanjan Ghosh, Martin Hutchings, Michael Dickinson, Monica Tani, Armando Santoro, Michael Crump, Amitkumar Mehta, Reinhard Marks, Martin Weisser, Martin Barrett, Chun Wu, Derrick Kaufman, Katharina Lechner, Pauline Baumlin, Pontus Lundberg, Max S. Topp   +16 more
wiley   +1 more source

Painful penile mass as an initial manifestation of systemic diffuse large B-cell lymphoma: a case report. [PDF]

Front Med (Lausanne)
Jan MJ, Liang CH, Ou MC, Tsao TY, Lin YS, Ou YC, Tung MC, Hsu CY.   +7 more
europepmc   +1 more source

LTB‐TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma

British Journal of Haematology, EarlyView.
LTB‐TREAT is a validated international prognostic model that identifies three groups of patients with distinct rates of time to treatment (TTT) in low tumour burden follicular lymphoma. The low‐risk group has a prolonged TTT with WW. The high‐risk group has early progression in whom treatment at diagnosis can be considered. Summary Watchful waiting (WW)
Luani Barge, Lachlan Webb, Anita Pelecanos, Niamh Waters, Ross Salvaris, Sam Lai, Tessa Potezny, Helen Cashman, Caitlyn Nguyen‐Ngo, Denise Lee, Costas K. Yannakou, Nada Hamad, Adrien Chauchet, Sylvain Choquet, Cédric Rossi, Adélie Herbin, Lukshe Kanagaratnam, Cyrielle Rodier, Constantine S. Tam, Abir Bhattacharyya, Chan Y. Cheah, Eliza A. Hawkes, Kirk Morris, Eric Durot, Joshua Tobin, Greg Hapgood   +25 more
wiley   +1 more source

Diffuse large B-cell lymphoma presenting as nonspecific abdominal pain with subsequent ischemic stroke. [PDF]

Can Fam Physician
Abeyewardene K, Marcano-Maurera M, Suleman A, Watada B.   +3 more
europepmc   +1 more source

Predicted microbiome‐associated metabolic pathways are linked to immune checkpoint modulation in chronic lymphocytic leukaemia

British Journal of Haematology, EarlyView.
Summary Microbial metabolites are key regulators of host immunity, yet their functional impact in chronic lymphocytic leukaemia (CLL) remains unclear. Following up on our earlier observations of microbiome dysbiosis in CLL, we performed predictive metabolic profiling based on 16S ribosomal RNA (rRNA) sequencing of oral and stool samples collected from ...
Monika Szelest, Joanna Zaleska, Michał Kiełbus, Magdalena Paziewska, Marta Masternak, Ewa Wawrzyniak, Aleksandra Kotkowska, Monika Siemieniuk‐Ryś, Marta Morawska, Elżbieta Kalicińska, Paula Jabłonowska‐Babij, Tomasz Wróbel, Anna Wolska‐Washer, Jerzy Zdzisław Błoński, Tadeusz Robak, Krzysztof Giannopoulos   +15 more
wiley   +1 more source